Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Microvisk Technologies

Explore full profile

MEMS-based coagulation monitoring for point-of-care testing

Oxford, United KingdomFounded 2004Biotech & Life Sciences
Valuation $25–50M Last recorded · 2011
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Microvisk Technologies and the history behind them.

About Microvisk Technologies

Microvisk Technologies is a medical device company that developed a point-of-care coagulation monitoring system. The firm was founded in 2004 as a spin-out from the UK's Science and Technology Facilities Council, with initial backing from the Rainbow Seed Fund. The company's main facility is in Oxford, UK.

The core of Microvisk's offering is a system for patients on anticoagulant drugs like Warfarin to monitor their blood clotting time, measured as the prothrombin time (PT) or International Normalised Ratio (INR). The system comprises a handheld reader and disposable test strips, branded as the 'SmartStrip®'. This technology is based on a patented Micro-Electro-Mechanical System (MEMS), a departure from the optical or chemical reaction methods used by other devices on the market. The MEMS chip features a tiny cantilever that physically moves within a single drop of blood to measure its viscosity, allowing for direct clot detection. This solid-state system was designed to be robust, require a smaller blood sample, and be simpler for home use, much like a glucose monitor.

The company developed two main devices: the 'CoagMax®' for point-of-care professional use and the 'CoagLite®' for patient self-testing at home. The business model focused on selling these handheld monitors and the recurring revenue from the disposable SmartStrips. These strips contain a memory chip that stores calibration and batch data, which is automatically uploaded to the reader to improve accuracy and ease of use. The devices aimed to serve the millions of patients on long-term anticoagulation therapy who require frequent monitoring, offering a more convenient alternative to regular clinic visits. After securing significant funding from investors including Porton Capital, Oxford Technology Management, Midven, and Finance Wales, Microvisk initiated clinical trials and prepared for product launches in the UK, Germany, and the US around 2011-2012. According to a public filing, the company was acquired or merged in May 2016.

Source: Dealroom company data

At a glance

Founded
2004
Headquarters
Oxford, United Kingdom
Sector
Biotech & Life Sciences

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • Future Planet Capital
  • Porton Group

Series B and later3 investors entered at this stage

  • Oxford Technology
  • Finance Wales
  • Future Planet Capital Regional
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇬🇧 United Kingdom100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Microvisk Technologies on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Microvisk Technologies on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.